{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.8","upperLimit":"47.8","value":"34.5"},{"groupId":"OG001","lowerLimit":"25.4","upperLimit":"67.3","value":"41.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Competing risk analysis was conducted to estimate the 2-year intrahepatic (progression outside of ablation zone), considering the progression of the ablated tumor and treating death as a competing event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors","id":"OG000","title":"Experimental"},{"description":"Morfeus software was not used during percutaneous ablation of hepatic mets","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"The 2-year secondary endpoints are provided in this analysis","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Intrahepatic Progression-free Survival (for the Randomized Group)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}